Business Parks & Science Centres

 
 
 

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Apitope International N.V.. (1/8/14). "Press Release: Apitope Led Consortium Receives Up to €6m FP7 Funding to Develop Novel Therapeutic Vaccine for Graves’ Disease". Bristol & Hasselt.

Organisations Organisation Apitope International N.V.
  Group Apitope (Group)
  Organisation 2 DAVIAD project (EU FP7)
Products Product therapeutic vaccine
  Product 2 clinical research
Index term Index term Apitope–College Group: public relations, 201211 service existent by College Hill
Person Person Martin, Keith (Apitope 201810 Non-Executive Director before 2006–201810 CEO RETIRED 10/18)
     


Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 (FP7) Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

Graves' disease is an immune system disorder that eventually results in the overproduction of thyroid hormones (hyperthyroidism). While a number of disorders may result in hyperthyroidism, Graves' disease is the most common cause affecting 2% of the female population. Symptoms of hyperthyroidism can include increased heart rate, muscle weakness, disturbed sleep, and irritability. Patients may also develop bulging eyes (proptosis). The disease affects multiple systems of the body, including the skin, heart, circulation and nervous system.

Apitope's antigen-specific disease modifying peptide therapy uses epitopes designed to shut down the abnormal immune responses to the causative agent in a highly selective manner, re-instating the normal immune balance, thereby avoiding global immune suppression. As a result, the peptides taken into clinical evaluation by Apitope offer the potential to have limited side effects and a good probability of efficacy.

Dr. Keith Martin, CEO of Apitope stated: "Graves' Disease is a disease with serious implications particularly for those with Graves' orbitopathy who are at risk of blindness. Current treatments for this disease may result in abnormally low thyroid activity levels, requiring further medications, and do not treat the fundamental cause of Graves' disease nor reduce the long term cardiac risks. This funding will allow a team of experts to develop a much needed therapy that may address the cause of this serious condition rather than simply treating the symptoms and removing the need for other medications."

Professor Neil Williams, CSO of KWS BioTest said: "This is a really exciting approach to the treatment of an important human disease, which builds on the successes that Apitope has seen in its MS programme. We are looking forward to applying our expertise in the preclinical immunology and inflammation areas to help drive the project forwards into the clinic. The award of the EU grant helps to cement the close drug discovery partnership in the consortium."

-ends-

For further information:

Apitope International N.V.
Dr. Keith Martin, CEO
+44 117 370 7720
keith.martin@apitope.com

For media enquiries:
College Hill
Melanie Toyne Sewell / Gemma Howe
+44 20 7866 7860
apitope@collegehill.com

Registered Addresses:

Apitope Technology (Bristol) Ltd., Bristol & Bath Science Park, Dirac Crescent, Bristol BS16 7FR, England;
Company Registration #: 442 5595; VAT Registration #: 794 3924 83.

Apitope International NV,Agoralaan, geb. A-bis, 3590 Diepenbeek, Belgium;
Company Registration Number BE 080 725 3103

   
Record changed: 2016-01-10

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Apitope (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top